Pfizer (PFE) Q2 FY25 earnings call

Pfizer delivered a strong Q2 FY25, driven by robust operational performance across its commercial portfolio and significant advancements in its R&D pipeline. The company raised its full-year adjusted EPS guidance, reflecting efficient cost management and favorable foreign exchange, while navigating policy-related headwinds such as the IRA and potential tariff impacts. Management remains focused on strategic capital allocation and leveraging technology to enhance productivity and expand margins.